A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae.

Autor: George PM; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK.; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK., Reed A; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK.; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK., Desai SR; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK.; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK., Devaraj A; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK.; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK., Faiez TS; Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, London SW7 2DD, UK., Laverty S; Section of Virology, Department of Infectious Disease, Imperial College London, London W2 1PG, UK., Kanwal A; Faculty of Health, Medicine and Wellbeing, Hunter Medical Research Institute, University of Newcastle, Callaghan, NSW 2308, Australia., Esneau C; Faculty of Health, Medicine and Wellbeing, Hunter Medical Research Institute, University of Newcastle, Callaghan, NSW 2308, Australia., Liu MKC; Section of Virology, Department of Infectious Disease, Imperial College London, London W2 1PG, UK., Kamal F; Royal Berkshire Hospital, Reading RG1 5AN, UK., Man WD; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK.; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.; Faculty of Life Sciences and Medicine, King's College London, London WC2R 2LS, UK., Kaul S; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK., Singh S; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK., Lamb G; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK., Faizi FK; Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, London SW7 2DD, UK., Schuliga M; Faculty of Health, Medicine and Wellbeing, Hunter Medical Research Institute, University of Newcastle, Callaghan, NSW 2308, Australia., Read J; Faculty of Health, Medicine and Wellbeing, Hunter Medical Research Institute, University of Newcastle, Callaghan, NSW 2308, Australia., Burgoyne T; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK.; UCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK., Pinto AL; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK., Micallef J; Belgian Volition SRL, 22 rue Phocas Lejeune, Parc Scientifique Créalys, Isnes 5032, Belgium., Bauwens E; Belgian Volition SRL, 22 rue Phocas Lejeune, Parc Scientifique Créalys, Isnes 5032, Belgium., Candiracci J; Belgian Volition SRL, 22 rue Phocas Lejeune, Parc Scientifique Créalys, Isnes 5032, Belgium., Bougoussa M; Belgian Volition SRL, 22 rue Phocas Lejeune, Parc Scientifique Créalys, Isnes 5032, Belgium., Herzog M; Belgian Volition SRL, 22 rue Phocas Lejeune, Parc Scientifique Créalys, Isnes 5032, Belgium., Raman L; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK., Ahmetaj-Shala B; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK., Turville S; The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia., Aggarwal A; The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia., Farne HA; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.; The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.; Chest and Allergy Department, St Mary's Hospital, Imperial College NHS Trust, London W2 1NY, UK., Dalla Pria A; Section of Virology, Department of Infectious Disease, Imperial College London, London W2 1PG, UK.; Department of HIV and Genitourinary Medicine, Chelsea and Westminster NHS Foundation Trust, London SW10 9NH, UK., Aswani AD; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK.; Santersus AG, Buckhauserstrasse 34, Zurich 8048, Switzerland., Patella F; Kinomica Ltd, Biohub, Alderley Park, Alderley Edge, Macclesfield, Cheshire SK10 4TG, UK., Borek WE; Kinomica Ltd, Biohub, Alderley Park, Alderley Edge, Macclesfield, Cheshire SK10 4TG, UK., Mitchell JA; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK., Bartlett NW; Faculty of Health, Medicine and Wellbeing, Hunter Medical Research Institute, University of Newcastle, Callaghan, NSW 2308, Australia., Dokal A; Kinomica Ltd, Biohub, Alderley Park, Alderley Edge, Macclesfield, Cheshire SK10 4TG, UK., Xu XN; Section of Virology, Department of Infectious Disease, Imperial College London, London W2 1PG, UK., Kelleher P; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK.; Department of HIV and Genitourinary Medicine, Chelsea and Westminster NHS Foundation Trust, London SW10 9NH, UK.; Immunology of Infection Section, Department of Infectious Disease, Imperial College London, London W2 1PG, UK.; Department of Infection and Immunity Sciences, North West London Pathology NHS Trust, London W2 1NY, UK., Shah A; Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK.; MRC Centre of Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK., Singanayagam A; Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, London SW7 2DD, UK.
Jazyk: angličtina
Zdroj: Science translational medicine [Sci Transl Med] 2022 Nov 16; Vol. 14 (671), pp. eabo5795. Date of Electronic Publication: 2022 Nov 16.
DOI: 10.1126/scitranslmed.abo5795
Abstrakt: Interstitial lung disease and associated fibrosis occur in a proportion of individuals who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection through unknown mechanisms. We studied individuals with severe coronavirus disease 2019 (COVID-19) after recovery from acute illness. Individuals with evidence of interstitial lung changes at 3 to 6 months after recovery had an up-regulated neutrophil-associated immune signature including increased chemokines, proteases, and markers of neutrophil extracellular traps that were detectable in the blood. Similar pathways were enriched in the upper airway with a concomitant increase in antiviral type I interferon signaling. Interaction analysis of the peripheral phosphoproteome identified enriched kinases critical for neutrophil inflammatory pathways. Evaluation of these individuals at 12 months after recovery indicated that a subset of the individuals had not yet achieved full normalization of radiological and functional changes. These data provide insight into mechanisms driving development of pulmonary sequelae during and after COVID-19 and provide a rational basis for development of targeted approaches to prevent long-term complications.
Databáze: MEDLINE